← All Marizyme, INC filings

Marizyme, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
MRZM
Marizyme, INC
10-Q: Marizyme, Inc. Reports Q3 2024 Results, Cites Going Concern Uncertainty Amidst Restatement and Financial Constraints
Marizyme, Inc.'s Q3 2024 results reveal a net loss and highlight substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
OTC.Pink
MRZM
Marizyme, INC
10-Q: Marizyme Inc. Reports Q2 2024 Results: Revenue Declines Amidst Financial Constraints
Marizyme Inc. reported a decrease in revenue and a net loss for the second quarter of 2024, primarily due to financial constraints impacting production and operations.
OTC.Pink
MRZM
Marizyme, INC
10-Q: Marizyme Inc. Reports Q1 2024 Results: Revenue Declines Amidst Ongoing Financial Challenges
Marizyme Inc. reported a net loss of $6.2 million for the first quarter of 2024, with a significant decrease in revenue compared to the same period last year, highlighting ongoing financial challenges.